drugset
drugset / Trial / NCT05174585

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

NCT05174585 ↗

Phase 1/2 Completed 21 enrolled Jacobio Pharmaceuticals Co., Ltd. Merck Sharp & Dohme LLC · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is to evaluate the safety and tolerability of JAB-BX102 monotherapy and combination therapy with pembrolizumab in adult participants with advanced solid tumors.

Timeline

Start
2022-08-18
Primary completion
2025-05-09
Completion
2025-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject JAB-BX102 Monoclonal antibody — Intravenous
Subject Pembrolizumab Monoclonal antibody — Intravenous

Indications

cancer